1. Introduction {#sec1-cancers-11-01021}
===============

Breast cancer is the highest incidence cancer and the leading cause of cancer-related mortality among women \[[@B1-cancers-11-01021]\]. It cannot be considered a single disease because genetic and genomic variability together with clinicopathological features determine different stages and prognoses \[[@B2-cancers-11-01021]\]. Even though in breast cancer the major cellular burden is constituted by the so-called bulk tumor cells, other cell subpopulations with stem features, self-renewal capacity, and the ability to regenerate the bulk tumor cells can be identified \[[@B3-cancers-11-01021]\]. Because of similarities with the stem progenitors of normal tissues, these cells have been defined cancer stem cells (CSCs). They have been described in several cancers but breast cancer stem cells (BCSCs) were among the first to be identified and characterized \[[@B4-cancers-11-01021]\].

The first evidence of their role in tumorigenesis were inferred from the injection into a xenograft mouse model. CSCs were able to recreate the tumor while other cellular subtypes from the tumor bulk were not, hence they have also been defined as tumor-initiating cells \[[@B4-cancers-11-01021]\]. It remains to be clarified whether these cells derive from a stem cell that has undergone malignant transformation, or are the result of stem-program activation and dedifferentiation in a tumor cell \[[@B5-cancers-11-01021]\].

BCSCs have also been extensively studied for years because of two main features that are crucial in cancer prognosis and progression: (1) their capacity to induce the epithelial--mesenchymal transition (EMT), to undergo self-renovation, and ultimately to give birth to new bulk tumor cells \[[@B6-cancers-11-01021]\]; and (2) their resistance to conventional therapies \[[@B7-cancers-11-01021]\]. Many efforts have been put into a better characterization and identification of BCSCs in order to verify their prognostic value and their usefulness in the monitoring of therapeutic efficacy. CD44 and CD24 were among the first studied markers in order to identify the CSC population \[[@B4-cancers-11-01021]\]. Later, the enzyme aldehyde dehydrogenase (ALDH or ALDH-1) was identified as another marker of CSCs \[[@B8-cancers-11-01021]\]. Combined analysis for ALDH-1, CD44, and CD24 demonstrated the existence of two populations that partially overlapped but were not identical. However, they were both able to recreate a tumor in a xenograft, thus suggesting the existence of several sub-populations of CSCs \[[@B8-cancers-11-01021]\]. In parallel, a dysregulation of pathways of stemness and self-renewal such, as Wnt \[[@B9-cancers-11-01021]\], PI3K/Akt/FOXO \[[@B10-cancers-11-01021]\], TGF-β \[[@B11-cancers-11-01021]\], and Notch \[[@B12-cancers-11-01021]\], was found in CSCs; the same pathways were involved in tumor invasiveness, hematogenous spreading, and ultimately in metastases. Moreover, CSCs have been identified among the main actors in these processes \[[@B13-cancers-11-01021],[@B14-cancers-11-01021]\]. Many of the pathways identified are involved in the EMT, a cardinal step in cancer diffusion \[[@B15-cancers-11-01021]\]. This is a process of trans-differentiation from epithelial cells to mesenchymal cells, which are able to enter systemic circulation and diffuse to distant sites \[[@B16-cancers-11-01021]\]. Genes like *SNAIL*, *SLUG* and *TWIST* are overexpressed in cells undergoing EMT \[[@B17-cancers-11-01021]\], in CSCs \[[@B18-cancers-11-01021]\] and in circulating tumor cells (CTCs) \[[@B19-cancers-11-01021]\]. CSCs are capable to acquire both an epithelial/proliferating and a mesenchymal/invasive phenotype \[[@B20-cancers-11-01021]\]. They demonstrate a great plasticity and the capacity to switch between these two phenotypes playing probably a crucial role in EMT \[[@B21-cancers-11-01021]\]. Different CSC subpopulations have been identified among the pool of CTCs, confirming their capacity to enter the blood stream and spread distantly \[[@B19-cancers-11-01021]\]. Therefore, the enumeration of CTCs and the identification of the circulating CSCs among CTCs have been proposed as possible prognostic factors, as well as indicators of disease progression and metastatic risk \[[@B22-cancers-11-01021]\]. Therapies based on traditional clinicopathological markers, that usually target the tumor bulk, fail in eliminating CSCs \[[@B7-cancers-11-01021]\]. The quiescent state of CSCs inside the tumor microenvironment allows them to resist conventional drugs, which target mainly proliferating cells \[[@B23-cancers-11-01021]\]. Then, the CSCs' ability to proliferate and regenerate the tumor burden ultimately leads to relapse or progression of the disease \[[@B7-cancers-11-01021]\]. Preclinical studies and clinical trials have tried to establish novel therapeutic regimens that aim to eradicate also the stem component in the tumor for a complete control of the disease \[[@B24-cancers-11-01021],[@B25-cancers-11-01021],[@B26-cancers-11-01021]\]. In order to have a holistic approach to the tumor system, new and conventional drugs have been combined together in order to address bulk and BCSCs at the same time \[[@B27-cancers-11-01021]\].

Many useful markers for the characterization and identification of CSCs can be both possible therapeutic targets to eliminate BCSCs and indicators of response to therapy. Among these markers, there are molecules involved mainly in self-renewal and survival, such as Notch, Hedgehog, Wnt, PI3K/Akt/mTOR, IL-8, HER2 and the TGF-β pathway \[[@B27-cancers-11-01021]\]. New technologies in drug delivery, combined with gene targeting, differentiating agents, immunomodulatory, and cell-based therapies, are promising tools for developing effective CSC-targeted drugs against breast cancer.

2. Breast Cancer Stem Cells as Markers for Prognosis and Therapy Monitoring {#sec2-cancers-11-01021}
===========================================================================

2.1. Breast Cancer Stem Cells and Circulating Tumor Cells (CTCs) {#sec2dot1-cancers-11-01021}
----------------------------------------------------------------

As reported above, the epithelial--mesenchymal transition (EMT) is a crucial step in disease progression. EMT is an embryonic program that is re-activated in tumor cells. It confers features proper of mesenchymal cells to epithelial, which are non-motile cells, and gives them the ability to invade adjacent tissues and to disseminate under the influence of multiple cytokines, which are produced by the surrounding stroma \[[@B28-cancers-11-01021]\]. CSCs represent one of the leading actors in this process, which includes their transformation into circulating tumor cells (CTCs) \[[@B15-cancers-11-01021]\]. Given this close link to metastasis, CTCs have been studied for several years as a possible marker of metastatic disease ([Table 1](#cancers-11-01021-t001){ref-type="table"}) \[[@B29-cancers-11-01021]\] and they have been correlated to a worse prognosis in metastatic breast cancer \[[@B30-cancers-11-01021]\]. In 2004, the first prospective multicentric study, on metastatic breast cancer patients, demonstrated that five CTCs per 7.5 mL of peripheral blood was the best cut-off value in order to identify patients with a worse prognosis, and a reduced overall survival (OS) and progression-free survival (PFS).

In 2014, another multicentric study, undertaken on 1944 patients, confirmed the threshold of 5 CTCs per 7.5 mL as the most effective in order to stratify metastatic breast-cancer patients with worse prognosis and to create a better predictive model \[[@B31-cancers-11-01021]\]. In this study, the baseline CTC-count was an independent prognostic factor for OS and PFS. The baseline CTC-count was able to improve the prognostication of OS and PFS when it was added to a full clinicopathological model. A further improvement in the predictive ability of this model was attained through the addition of the CTC count at 3--5 weeks and at 6--8 weeks.

CTCs can be detected in peripheral blood even in the initial stages of the disease. A pooled analysis of data from 3173 patients with non-metastatic breast cancer (Stage I to III) demonstrated the presence of one or more CTCs in 20.2% of the patients \[[@B32-cancers-11-01021]\]. In this study, one CTC, or more, could be used as an independent prognostic factor for OS and disease-free survival (DFS).

Several ongoing clinical trials have measured CTCs in order to orient therapeutic decisions (DETECT III (NCT01619111); CirCe T-DM1 (NCT01975142); Treat CTC trial (NCT01548677; \[[@B33-cancers-11-01021],[@B34-cancers-11-01021],[@B35-cancers-11-01021]\]). Many of these trials have not presented the final survival analysis yet but results from published data are still conflicting.

Even though all the evidence confirms that CTCs have a high prognostic value, a lot of open issues still deserve further debate in order to be clarified.

All the studies cited above used the CellSearch^TM^ (Veridex) system, which is the only one approved by the Food and Drug Administration for the CTC detection in peripheral blood \[[@B36-cancers-11-01021]\] (CELLSEARCH^®^ Circulating Tumor Cell Kit (Epithelial) Instructions for Use. Janssen Diagnostics, LLC). It is a system based on the epithelial cell adhesion molecule (EpCAM), which targets CTCs with an epithelial phenotype only, thus having several limitations. For instance, circulating CSCs play an active role in the progression of the disease in metastases and in drug resistance. With the CellSearch^TM^ system, either they are cut-out from the count, or they are counted together with purely epithelial CTCs.

Standardized detection systems have not dealt with the extreme heterogeneity of CTCs yet. Furthermore, the significance of the CTC phenotype analysis still remains to be clarified.

In both EpCAM-positive and EpCAM-negative CTCs, the expression of Notch1, an important stemness marker, was correlated with brain metastases \[[@B12-cancers-11-01021],[@B37-cancers-11-01021]\]. In an ongoing trial, Notch1 has been used as a CTC marker (together with HER2, COX-2, EGFR, and ST6GALNAC5), in order to evaluate, through the CTC count, the risk of brain recurrences after focal radiotherapy (NCT02941536).

The estrogen receptor/progesterone receptor (ER/PR) status of CTCs was compared to that of the primary tumor in several studies. A concordance in between 40% and 70% was reported \[[@B38-cancers-11-01021],[@B39-cancers-11-01021],[@B40-cancers-11-01021],[@B41-cancers-11-01021]\]. Clinical significance of this discrepancy and the possible impact on therapeutic choices have not been evaluated yet.

Similarly, the HER2/neu status on CTCs matched only in a limited number of cases with that of the primary tumor. In two recent studies, the concordance rate of HER2/neu between CTCs and the primary tumor was about 60% \[[@B41-cancers-11-01021]\]. The clinical significance of this discrepancy is yet to be understood. In a metanalysis by Wang et al. \[[@B42-cancers-11-01021]\], the CTCs' HER2/neu status was a prognostic factor in non-metastatic patients only. One or more HER2/neu-positive CTCs were associated with a reduced OS and PFS. Clinical trials are ongoing in order to verify whether the treatment with drugs against HER2/neu could be beneficial in patients with HER2/neu positive CTCs, independently from the HER2/neu status of the primary tumor (NCT01619111 and NCT01975142).

Similarly, the genotypic analysis of CTCs for mutations of estrogen receptor gene *ESR1* \[[@B43-cancers-11-01021]\] for the altered HER2 expression \[[@B41-cancers-11-01021]\], for mutations in the PIK3CA gene \[[@B44-cancers-11-01021]\], and for the expression of stemness markers, as with the ALDH-1 gene \[[@B45-cancers-11-01021]\], is gaining ever more attention.

The different cellular populations among CTCs, which recapitulate those present in the primary tumor, are another critical point that should be considered. It is possible to distinguish epithelial CTCs, mesenchymal CTCs, and CTCs with a staminal phenotype, which could be both epithelial-mesenchymal (EM) or mesenchymal-epithelial (ME) \[[@B19-cancers-11-01021],[@B46-cancers-11-01021],[@B47-cancers-11-01021]\]. In this sense, a merely quantitative evaluation of the CTCs is not able to distinguish the prognostic meaning of the different CTC subpopulations.

CTC analysis can give a better insight into CSCs and their dynamic evolution during a cancer's natural history. The identification of stemness and EMT markers on CTCs could possibly help us in order to create an in depth profile of the primary tumor and the metastases and to target more precisely those cell populations, which are mostly responsible of the resistance to therapies, of the disease dissemination, and ultimately of a worse prognosis \[[@B4-cancers-11-01021],[@B24-cancers-11-01021],[@B48-cancers-11-01021]\]. For instance, 41% of patients with aggressive breast cancers (triple negative or HER2 + tumors) presented mesenchymal CTCs, which are not measured by the standard systems \[[@B19-cancers-11-01021]\].

AKT2, PI3Kα, and twist-related protein 1 (TWIST1) are the three main markers that are expressed by the epithelial-mesenchymal (EM) CTCs. These markers were evaluated by several groups in order to identify EM-CTCs \[[@B24-cancers-11-01021],[@B49-cancers-11-01021],[@B50-cancers-11-01021]\]. Patients with nodal involvement and metastatic breast cancer had a higher presence in systemic circulation of CTCs with the EM phenotype \[[@B51-cancers-11-01021],[@B52-cancers-11-01021]\]. An observational study analyzed epithelial CTCs, EM CTCs, and purely mesenchymal CTCs on 56 metastatic breast-cancer patients \[[@B53-cancers-11-01021]\]. Both epithelial CTCs and EM CTCs were significantly associated with a poorer OS, while only EM CTCs were correlated with a reduced PFS.

Another multicentric prospective study used a microfluidic system for the detection of different CTC populations and tried to establish a threshold in order to predict the PFS after one year \[[@B54-cancers-11-01021]\]. The patients with a total number of CTCs equal or superior to 10 and with a proportion of mesenchymal CTCs greater than 10.7% had a worse median PFS compared to the patients who did not meet these criteria.

Nonetheless, the methods used to count the different CTC populations are yet to be standardized and validated, and their prognostic and predictive value is unclear.

Among CTCs, the main markers associated with circulating CSCs are ALDH-1, CD44, and CD24, which are able to identify the cells with a higher metastatic potential \[[@B17-cancers-11-01021],[@B55-cancers-11-01021],[@B56-cancers-11-01021]\]. The breast CSCs can switch easily in between the EM phenotype (which is EpCAM^−^CD49f^+^ and expresses the CSC markers CD44^+^/CD24^−^) and the ME phenotype (which is EpCAM^+^CD49f^+^ and expresses the CSC marker ALDH-1^+^) \[[@B20-cancers-11-01021]\]. Circulating CSCs with the EM phenotype can be identified with EpCAM-based systems, but it is not possible to distinguish them from the purely epithelial CTCs without further analysis \[[@B6-cancers-11-01021]\]. Matrigel invasion assays with these two circulating CSC subpopulations (EM-CSCs and ME-CSCs) showed that CSCs with an EM phenotype have a greater invasive capacity than ME CSCs \[[@B20-cancers-11-01021]\]. This could be in favor of the theory that hypothesizes that CSCs from the primary tumor undergo EMT on the invasive front and enter the circulation, thus spreading to distant sites. Micro-metastases are quiescent until these CSCs revert to a mesenchymal/epithelial, "self-renewing" phenotype, and originate the new bulk tumor. Nonetheless, the clinical impact of these markers expressed on CTCs remains unclear.

The analysis and the dosage of circulating tumor DNAs and micro-RNAs are other promising options in order to profile CSCs and to evaluate the minimal residual disease \[[@B57-cancers-11-01021]\]. A Taiwanese study dosed the levels of two micro-RNA (miR-9 and miR-221) in 206 patients. MiR-9 and miR-221 have been associated with stemness features, elevated metastatic potential, and EMT activation. In this study, high levels of MiR-9 and miR-221 were independently associated with a poorer OS and DFS after 8 years of follow-up \[[@B58-cancers-11-01021]\]. Nonetheless, the prognostic and predictive values of these markers are still far to be fully understood \[[@B59-cancers-11-01021]\].

2.2. Analysis of the Cancer Stem Cells in the Primitive Tumor {#sec2dot2-cancers-11-01021}
-------------------------------------------------------------

Even though it is easier to access and to monitor blood parameters like stem CTCs over time, the analysis of the tumoral specimens still remains of pivotal importance in order to characterize CSCs and try to understand disease prognosis and the possible response to therapies. ALDH-1, CD44, and CD24 were among the first markers that were evaluated regarding primary tumors through immunohistochemistry in order to identify the CSC population, even though the data about their clinical prognostic value are still contradictory. Quantitative immunofluorescence for ALDH-1^+^ and CD44^+^/CD24^−^ cells was retrospectively evaluated on 639 patients with 12.6 years of follow up. Co-expression of these markers correlated significantly with a worse outcome independently of the tumor size, grade, nodal status, and HER2/neu and receptor status, while the ALDH-1 alone did not significantly predict an outcome \[[@B60-cancers-11-01021]\]. In a study on 144 patients with invasive ductal carcinoma, neither immunohistochemical ALDH-1^+^ nor CD44^+^/CD24^−^ correlated with a difference in OS \[[@B61-cancers-11-01021]\]. In another study on 121 patients, a positive immunohistochemical staining, both for ALDH and CD44/CD24, was evaluated. A positive staining for ALDH-1 was significantly correlated with a higher rate of metastasis or recurrence \[[@B62-cancers-11-01021]\]. The staining for CD44^+^/CD24^−^ cells was not significantly associated per se with metastasis or recurrence even though a higher proportion of these cells in the tumor showed a significant association with metastatic disease and recurrences.

Other authors highlighted that ALDH-1 is a marker of invasiveness and metastatic potential, while the CD44^+^/CD24^−^ ratio indicates mainly a "self-renewal" capacity, thus these two markers are assigned different functions during the tumor progression. Therefore, they advocated always combining the use of both the markers for the sake of a better understanding of the stem population \[[@B63-cancers-11-01021]\].

Many authors tried to develop a molecular "fingerprint" of the tumor in order to have a deeper comprehension of CSC role in breast cancer evolution and to draw reliable prognostic conclusions. Gwak et al. analyzed the tumoral expression of several transcription factors proper of the embryonic stem cells, including Oct4, Sox2, Nanog, Bmi1, and Klf4 \[[@B64-cancers-11-01021]\]. Expression of Oct4 correlated with ALDH-1 positivity, a high Ki-67 and a high histological grade, and it was an independent prognostic factor for a reduced DFS. These associations were found specifically in the hormone receptor (HR)-positive group and in the HR-positive patients in treatment with tamoxifen. This is possibly another hint in favor of a previously suggested association between Oct-4 and tamoxifen resistance \[[@B65-cancers-11-01021]\]. It was proposed that one should combine different multi-gene prognostic signatures that address 17 specific genes (HTICS), each of them with roles in three different major pathways in the tumor biology: immune response, cell migration, and cell proliferation \[[@B66-cancers-11-01021]\]. These genes were selected among those expressed more by the tumor-initiating cells than by the non-tumor-initiating ones, thus obtaining a prognostic tool that was able to predict metastasis-free survival (MFS) and OS in HER2^+^/ERα^−^ cancer patients. Despite the reduction of the signature to a six-gene panel, the authors highlighted that there was still a significant prognostic value, even if reduced.

The importance of the selection of a genetic signature of CSCs and not only of the bulk tumor has been recently demonstrated and clinically validated for a panel of 20 genes in order to add prognostic and predictive value to clinical models. \[[@B67-cancers-11-01021]\]. This 20-gene signature was selected among a set of stem-cell-specific genes overexpressed in mammary stem cells. The genetic signatures derived from bulk tumoral cells frequently overlapped clinicopathological features, thus reducing their prognostic ability in cases like triple-negative breast cancers, which lack expression of hormone receptors and have a high proliferation rate. This panel was clinically validated on a cohort of 2453 breast cancers and it was able to predict the risk of distant metastases in triple-negative (TNBC) and luminal breast cancers, independent of standard clinicopathological parameters.

A better understanding of CSCs both circulating and quiescent in the primitive tumor bulk can lead to a better prognosis prediction, therapy allocation, and ultimately to the development of targeted treatments for these cells, which are often resistant to conventional chemotherapy.

3. Breast Cancer Stem Cell-Targeting: New Strategies in Drug Development for Therapy Resistance {#sec3-cancers-11-01021}
===============================================================================================

Conventional drugs targeting the tumor bulk are ineffective at eradicating CSCs \[[@B7-cancers-11-01021]\]. In particular, it has been reported that anti-mitotic agents, such as taxanes (paclitaxel and docetaxel), cannot target quiescent CSCs inside the tumor bulk \[[@B23-cancers-11-01021]\], leading to the reconstitution of the initial tumor cell population, increasing the adhesiveness of CTCs and the disease progression \[[@B68-cancers-11-01021],[@B69-cancers-11-01021]\]. Based on this evidence, some studies have focused on directly targeting CSC subpopulation with promising results from preclinical experiments and clinical trials \[[@B24-cancers-11-01021],[@B25-cancers-11-01021],[@B26-cancers-11-01021]\]. Novel therapeutic strategies for BCSC-targeting are based on the combined use of new and conventional drugs \[[@B27-cancers-11-01021]\]. In particular, the main targets for BCSCs are Notch, Hedgehog, Wnt, PI3K/Akt/mTOR, IL-8, HER2, and TGF-β signaling, which are implicated in BCSC self-renewal and survival \[[@B27-cancers-11-01021]\]. Moreover, the application of nano and biotechnologies, combined with gene targeting, represents a promising strategy for the development of effective BCSC-targeted drugs. An overview of the main strategies based on BCSC-targeting is shown in [Figure 1](#cancers-11-01021-f001){ref-type="fig"}.

3.1. Signaling Pathways Activated in Breast Cancer Stem Cells {#sec3dot1-cancers-11-01021}
-------------------------------------------------------------

### 3.1.1. Notch Signaling {#sec3dot1dot1-cancers-11-01021}

The most clinically developed approach is the inhibition of the Notch signaling by γ-secretase inhibitors (GSIs). Notch receptors are cleaved by γ-secretase, which determines the release of the Notch intracellular domain (NCID), and subsequently, Notch signaling activation. Then, NCID is translocated to the nucleus where it induces gene transcription by interacting with other co-factors \[[@B70-cancers-11-01021],[@B71-cancers-11-01021]\]. Notch signaling is highly active in BCSCs and it associates with tumor invasiveness \[[@B72-cancers-11-01021]\]. The use of γ-secretase inhibitors has been proven effective in blocking the Notch pathway \[[@B72-cancers-11-01021]\] and BCSC capability to form mammospheres in vitro \[[@B73-cancers-11-01021]\]. Different phase I/II clinical trials using the γ-secretase inhibitor MK-0752 (Merck) in combination with docetaxel are ongoing for the treatment of metastatic breast cancer \[[@B73-cancers-11-01021]\]. Enrolled patients' biopsies demonstrated a significant reduction in BCSC number, sustaining the advantages of Notch pathway inhibitors for BCSC-targeted therapy. In addition, other GSIs are in use to treat metastatic breast cancer such as RO4929097 (also combined with paclitaxel and carboplatin), PF-03084014, LY3039478, and CB-103 ([Table 2](#cancers-11-01021-t002){ref-type="table"}).

### 3.1.2. Hedgehog Signaling {#sec3dot1dot2-cancers-11-01021}

Hedgehog signaling is implicated in the maintenance of CSC stemness and in the regulation of self-renewal, survival, angiogenesis, EMT, and cell invasion \[[@B74-cancers-11-01021]\]. Different inhibitors of the Hedgehog pathway, such as vismodegib, have been investigated, also in clinical trials, for their anti-CSC activity. In particular, an ongoing phase I clinical trial is evaluating the effects of vismodegib and RO4929097 on BCSC differentiation markers ([Table 2](#cancers-11-01021-t002){ref-type="table"}). Sims-Mourtada et al. co-treated breast cancer cells with vismodegib and docetaxel and found a decrease in the BCSC number and mammosphere formation that were increased instead by docetaxel alone \[[@B75-cancers-11-01021]\]. In addition, they reported a Hedgehog signaling-dependent induction of multi-drug resistance 1 (MDR1) and ATP-binding cassette super-family G member 2 (ABCG2) in BCSCs. The Hedgehog inhibitor vismodegib (GDC-0449) has also been proven to counteract tumor growth in tamoxifen-resistant breast cancer xenografts \[[@B76-cancers-11-01021]\].

### 3.1.3. Wnt Pathway {#sec3dot1dot3-cancers-11-01021}

It has been reported that the Wnt pathway is highly active in BCSCs compared with the remaining tumor cells \[[@B77-cancers-11-01021]\]. Different targets for Wnt pathway inhibition have been investigated, such as Porcupine O-Acyltransferase (PORCN), R-spondin-3 (RSPO3), Wnt family member 2B (WNT2B), Frizzled-5 (FZD5), FZD10, Tyrosine-protein kinase transmembrane receptor 1 (ROR1), tankyrase, and β-catenin, and some drugs have reached clinical trials \[[@B78-cancers-11-01021]\] ([Table 2](#cancers-11-01021-t002){ref-type="table"}). In particular, monoclonal antibodies targeting the Wnt pathway, such as vantictumab (OMP-18R5) and cirmtuzumab (UC-961), anti-Frizzled and anti-ROR1, have proven effective, in combination with paclitaxel, in treating metastatic breast cancer. A clinical trial is recruiting breast cancer patients in order to determine the effective dose of LGK-974 (WNT974), a PORCN inhibitor, that counteracts the palmitoylation and secretion of Wnt ligands, alone or in combination with immunotherapy (an anti-Programmed Death 1/PD-1 antibody). LGK-974 has proven effective in different in vitro and in vivo cancer models \[[@B79-cancers-11-01021]\]. Moreover, two clinical trials are using Foxy-5, a Wnt5a mimicking peptide, as an anti-metastatic cancer drug. In a study by Hallett et al., the Wnt signaling inhibitor PKF118-310 has been reported to be effective in reducing tumor growth and BCSC number in HER2-overexpressing breast cancer xenografts \[[@B80-cancers-11-01021]\]. ROR1 is a type I orphan receptor expressed exclusively on different tumor cell types \[[@B81-cancers-11-01021]\]. ROR1 is mainly involved in EMT and metastasis and its silencing in breast cancer cells counteracted these processes in vivo \[[@B81-cancers-11-01021]\].

### 3.1.4. PI3K/Akt/mTOR Pathway {#sec3dot1dot4-cancers-11-01021}

The PI3K/AKT/mTOR pathway regulates BCSC functions \[[@B52-cancers-11-01021]\]. The inhibition of the PI3K/Akt/mTOR pathway by everolimus (RAD001) has been reported to counteract BCSC proliferation in primary breast cancer cells, especially in combination with docetaxel \[[@B114-cancers-11-01021]\]. Combined treatment of everolimus and an aromatase inhibitor increased the progression-free survival in advanced hormone receptor-positive breast cancer patients \[[@B93-cancers-11-01021]\] ([Table 2](#cancers-11-01021-t002){ref-type="table"}).

### 3.1.5. Ephrin/Ephrin Receptor Pathway {#sec3dot1dot5-cancers-11-01021}

Ephrin receptors, belonging to the largest family of receptor tyrosine kinases (RTKs), have been reported to influence BCSC activity \[[@B115-cancers-11-01021]\] and several molecules targeting this pathway are being tested in clinical trials, especially the tyrosine kinase inhibitors. Ephrin A4 has been reported to be a potential therapeutic target for BCSCs \[[@B116-cancers-11-01021],[@B117-cancers-11-01021]\]. An antibody-drug conjugate targeting Ephrin A4, named PF-06647263, consisting of a humanized monoclonal antibody anti-Ephrin A4 conjugated to the DNA-damaging agent calicheamicin, has been developed and tested to induce tumor regression in TNBC xenografts in vivo \[[@B117-cancers-11-01021]\]. Moreover, PF-06647263 is currently being evaluated in a phase I clinical trial in metastatic TNBC patients ([Table 2](#cancers-11-01021-t002){ref-type="table"}).

### 3.1.6. Chemokine Ligand 8-Chemokine Receptor Type 1/2 (CXCL8-CXCR1/2) Axis {#sec3dot1dot6-cancers-11-01021}

Many studies have focused attention on the role of IL-8 (CXCL8) in the biology of BCSCs. CXCL8 is a chemokine whose biological effects are mediated by two G-protein-coupled receptors: CXCR1 and CXCR2 \[[@B118-cancers-11-01021]\]. CXCL8 has been reported to play multiple roles in cancer, such as increasing proliferation, angiogenesis, and metastases \[[@B119-cancers-11-01021]\], as well as in mammosphere formation in HER2-positive breast cancer \[[@B120-cancers-11-01021]\]. The adding of exogenous CXCL8 has proven to be effective in promoting the proliferation of CSCs in vitro; this growth was prevented by the presence of CXCR1/2 antagonists, such as reparixin \[[@B121-cancers-11-01021]\] or a monoclonal antibody anti-CXCR1 (but not anti-CXCR2) \[[@B122-cancers-11-01021]\]. These results have also been confirmed in breast cancer cell lines and in breast cancer patient-derived xenografts, in which the combination of docetaxel and reparixin was more effective in reducing tumor growth than either treatment alone, with a significant decrease in CSC number through apoptosis by activating Fas/FasL signaling \[[@B122-cancers-11-01021]\] ([Table 2](#cancers-11-01021-t002){ref-type="table"}). In addition, the combined treatment with reparixin and paclitaxel in the human TNBC cell line MDA-MB231 showed a synergistic effect, as proven for mammosphere activity and cell cycle arrest, likely mediated by the inhibition of focal adhesion kinase (FAK)/AKT and cyclin B1 signaling \[[@B123-cancers-11-01021]\]. Neutralizing anti-CXCR1 and anti-CXCL8 monoclonal antibodies induced the same results \[[@B123-cancers-11-01021]\]. SCH563705, another CXCR1/2 inhibitor, has been reported to counteract the effects of exogenous CXCL8 on BCSC mammosphere activity \[[@B120-cancers-11-01021]\]. Currently, two clinical trials (phase I and II) are evaluating the efficacy of reparixin on BCSC survival (the first in combination with paclitaxel) ([Table 2](#cancers-11-01021-t002){ref-type="table"}). In the ongoing phase Ib clinical study \[[@B124-cancers-11-01021]\], patients with HER-2 negative metastatic breast cancer who received reparixin and paclitaxel showed no cytotoxic effects and are in long-term remission \[[@B124-cancers-11-01021]\]. However, it was not possible to collect serial biopsies of tumor tissue at baseline and during treatment. No significant differences in CTC number, ALDH expression, and EMT transcription factors were observed, likely due to the small sample size and high baseline heterogeneity.

A pilot trial (NCT01861054) of single agent reparixin that is evaluating the efficacy of reparixin to eliminate CSC in primary operable breast cancer \[[@B97-cancers-11-01021]\] found the same limitations. A randomized, placebo-controlled clinical trial is using paclitaxel with and without reparixin in a front-line treatment of metastatic TNBC with good tolerability \[[@B124-cancers-11-01021]\].

### 3.1.7. EGFR/HER2 and TGF-β Signaling {#sec3dot1dot7-cancers-11-01021}

Several molecules targeting EGFR/HER2 signaling (downstream of IL-8) have been intensively investigated in breast cancer. In particular, Lapatinib (a HER2 inhibitor) has proven effective in counteracting tumor growth of HER2-positive and negative breast cancers, showing moderate toxicity and a decrease in brain metastases \[[@B125-cancers-11-01021]\]. Currently, some clinical trials are evaluating the efficacy of Lapatinib on BCSCs \[[@B25-cancers-11-01021]\] ([Table 2](#cancers-11-01021-t002){ref-type="table"}). Trastuzumab (Herceptin), an inhibitor of HER2, has been proven to target HER2-expressing BCSCs and inhibit the tumor growth of patient-derived xenografts from HER2-negative breast cancer \[[@B126-cancers-11-01021]\].

Given the critical role of TGF- β signaling in EMT and CSC activity, its inhibition has proven to be a promising strategy against drug resistance in chemotherapy \[[@B92-cancers-11-01021]\]. The blocking of TGF-β signaling by a TGF-β type I receptor kinase inhibitor, EW-7197, suppressed paclitaxel-induced EMT and CSC mammosphere formation, reducing the number of lung metastases and increasing survival time in vivo \[[@B127-cancers-11-01021]\]. Moreover, the cross-talk between the TGF-β pathway and Notch signaling in BCSCs has been demonstrated \[[@B128-cancers-11-01021],[@B129-cancers-11-01021]\]. Currently, many different inhibitors of TGF-β pathway are being tested. One of the main is the TGF-β type I RTK inhibitor galunisertib/LY2157299. It has been reported that LY2157299 inhibited CSC expansion induced by paclitaxel alone in TNBC cell lines and in mouse xenografts \[[@B92-cancers-11-01021]\]. Moreover, LY2157299 prevented tumor regrowth after paclitaxel treatment \[[@B92-cancers-11-01021]\]. The evidence of a cardiovascular toxicity of LY2157299 has emerged in some preclinical studies \[[@B130-cancers-11-01021],[@B131-cancers-11-01021]\], but now with the appropriate administration protocols, this issue has been overcome \[[@B132-cancers-11-01021]\]. Some clinical trials are studying the efficacy of LY2157299 but none of these trials is explicitly referring to its anti-CSC activity ([Table 2](#cancers-11-01021-t002){ref-type="table"}).

Disulfiram, used for chronic alcoholism treatment, is a dithiocarbamate that acts as an inhibitor of ALDH activity \[[@B133-cancers-11-01021]\]. It has been reported that disulfiram inhibited TGF-β-induced EMT and CSC markers in breast cancer \[[@B134-cancers-11-01021]\].

In addition, antibodies targeting clusterin, a stress-activated and apoptosis-associated molecular chaperone also overexpressed in breast cancer \[[@B135-cancers-11-01021]\], have been reported to inhibit TGF-β-induced EMT and to reduce lung metastasis in breast cancer models \[[@B136-cancers-11-01021],[@B137-cancers-11-01021]\]. In particular, a humanized anti-clusterin mAb (AB-16B5) has been tested in patients with advanced solid tumors that showed an inhibition of EMT markers in the tumor biopsies after treatment \[[@B91-cancers-11-01021]\] ([Table 2](#cancers-11-01021-t002){ref-type="table"}).

### 3.1.8. Angiogenic Signaling Pathway {#sec3dot1dot8-cancers-11-01021}

Angiogenesis is critically required for cancer development and its inhibition by blocking vascular endothelial growth factor (VEGF) with the monoclonal antibody bevacizumab has been studied in the treatment of different types of cancers \[[@B138-cancers-11-01021]\]. However, these studies reported conflicting opinions on its efficacy. In fact, the antiangiogenic therapy has reported to promote BCSC proliferation driven by hypoxia, limiting the efficacy of antiangiogenic drugs \[[@B139-cancers-11-01021]\]. These findings suggest that antiangiogenic drugs should be combined with CSC-targeted therapies to improve cancer patient outcome. BCSC activity can be induced by hypoxia through a hypoxia-inducible factor 1α (HIF-1α) mediated pathway \[[@B140-cancers-11-01021],[@B141-cancers-11-01021]\]. The blocking of HIF-1α by specific inhibitors, such as ganetespib (a second-generation HSP90 inhibitor), has been reported to be effective in counteracting chemoresistance induced by a paclitaxel or gemcitabine treatment, as demonstrated by in vitro and in vivo studies \[[@B140-cancers-11-01021],[@B141-cancers-11-01021]\]. A phase I clinical trial evaluated the efficacy of a ganetespib treatment in trastuzumab-resistant HER2-positive metastatic breast cancer patients, reporting a good tolerability and slowing down of the progression \[[@B96-cancers-11-01021]\] ([Table 2](#cancers-11-01021-t002){ref-type="table"}). Another hypoxia-related strategy consists of inhibiting HIF-1α- and HIF-2α-dependent expression of AlkB homolog 5 (ALKBH5) leading to the downregulation of NANOG, a pluripotency key gene in CSCs \[[@B142-cancers-11-01021]\].

3.2. New Nano and Biotechnologies Applied to BCSC-Targeting Therapies {#sec3dot2-cancers-11-01021}
---------------------------------------------------------------------

Nanotechnology could offer potential solutions for the specific targeting of BCSCs. The aim of nanoparticle technology is to promote the delivery of chemotherapeutic drugs to the tumor site using engineered drug-loaded nanoparticles targeting BCSCs. Currently, an ongoing phase I clinical trial is using lyso-thermosensitive liposomal doxorubicin (LTLD, ThermoDox; Celsion Corporation, NJ, USA) to achieve higher local drug concentrations in metastatic HER2-negative breast cancer patients (NCT03749850) \[[@B143-cancers-11-01021]\]. In addition, nanoparticle albumin-bound (nab)-paclitaxel, in association with atezolizumab, has been proven effective in metastatic TNBC patients (NCT02425891) \[[@B144-cancers-11-01021]\]. Moreover, nanoparticles are commonly used as RNA/DNA carriers in order to prevent degradation and ensure the delivery to the tumor site (see [Section 3.2.3](#sec3dot2dot3-cancers-11-01021){ref-type="sec"} on gene-targeted therapies). Several preclinical studies gave promising results using nanoparticles. In particular, salinomycin-loaded PEGylated polymeric micelles have proven effective in targeting BCSCs in vivo more than salinomycin alone \[[@B145-cancers-11-01021]\]. Other strategies are based on the identification, by specific antibodies or ligands loaded onto nanoparticles, of particular receptors overexpressed on BCSCs \[[@B145-cancers-11-01021]\]. For example, an anti-CD44 antibody conjugated to gold nanorod has been used to target and photo-ablate CD44^+^ subpopulations from three-dimensional MCF-7 mammospheres \[[@B146-cancers-11-01021]\]. Promising results come from the use of salinomycin-loaded nanoparticles coated with hyaluronan (HA), a ligand of CD44. The treatment with these nanoparticles has proven to increase the cellular uptake and specifically target BCSCs \[[@B147-cancers-11-01021]\]. Recently, Han et al. reported the efficacy of HA-conjugated liposomes loaded with gemcitabine in killing BCSCs with a lower systemic toxicity compared with the drug alone in experimental models \[[@B148-cancers-11-01021]\]. Different strategies for HA targeting are under consideration; in particular, the use of small HA oligosaccharides competing with an endogenous HA polymer \[[@B149-cancers-11-01021]\] and the use of antibodies blocking the HA-binding site of CD44 \[[@B150-cancers-11-01021]\] have proven efficacious.

### 3.2.1. Immunomodulatory Therapy {#sec3dot2dot1-cancers-11-01021}

The genetic engineering of autologous T lymphocytes or dendritic cells (DCs) and cancer vaccines (anti-CSCs or associated-individual proteins) represent promising strategies to elicit a specific antitumor immune response against cancer \[[@B151-cancers-11-01021]\].

The high levels of lymphocytic infiltration is significantly associated with a more-favorable prognosis in patients with early stage TNBC and HER2-positive breast cancer \[[@B152-cancers-11-01021]\]. This infiltration indicates a host antitumor immune response, fundamental for the survival outcome. Recent trials have shown that the targeting of the PD-1 and PD-L1 axis was also clinically effective in metastatic TNBC \[[@B152-cancers-11-01021]\]. In particular, the transduction of T-cell with siRNA against PD-1 ligands or a PD-1/CD28 fusion receptor represents a novel immunotherapy application in breast cancer \[[@B153-cancers-11-01021],[@B154-cancers-11-01021]\].

Moreover, T-cells can be genetically modified to express a novel T cell receptor (TCR) or a chimeric antigen receptor (CAR) that specifically recognize a tumor-associated antigen, inducing the cytolysis of the target cell \[[@B155-cancers-11-01021]\]. However, some limitations are due to the downregulation of HLA class I (antigen presentation) and the required compatibility between patient's HA haplotype and the TCR \[[@B155-cancers-11-01021]\]. CAR-T cells are engineered T-cells able to target a specific tumor protein expressing chimeric receptors (CARs) that combine both antigen-binding sites and T-cell activating functions by intracellular signaling motifs \[[@B155-cancers-11-01021]\]. This system is independent from HLA and can recognize many targets other than peptides \[[@B156-cancers-11-01021]\].

DCs, involved in the antigen processing and presentation, are currently exploited for their potential antitumor activity. In particular, some studies reported the genetic engineering of tumor cells and their fusion with DCs \[[@B157-cancers-11-01021],[@B158-cancers-11-01021]\]. In addition, DCs can be loaded with tumor antigens or peptides and transfected with tumor-derived RNA or DNA \[[@B157-cancers-11-01021],[@B158-cancers-11-01021]\]. In breast cancer, DCs expressing breast cancer antigens and transfected with siRNA against indoleamine 2,3-dioxygenase have been proven effective in reducing tumor growth and increasing survival in mouse models \[[@B159-cancers-11-01021],[@B160-cancers-11-01021]\].

Therapeutic vaccines are able to stimulate a reactive and competent immune response against tumor antigens. Vaccines can be derived from whole tumor cell lysates, proteins, peptides, DNA, or DCs \[[@B151-cancers-11-01021]\]. Immune cells are able to affect CSCs in vitro and are promising candidates for new strategies in breast cancer immunotherapy \[[@B151-cancers-11-01021]\]. Currently, whole-cell vaccines showed inconsistency regarding the clinical efficacy in cancer patients \[[@B161-cancers-11-01021]\]. Several vaccinations against anti-CSC individual proteins have been investigated in breast cancer ([Table 2](#cancers-11-01021-t002){ref-type="table"}). In a preclinical study, vaccination against sodium-independent cystine-glutamate antiporter (xCT), the functional subunit of the cysteine/glutamate antiporter system xc-, has been proven effective in the inhibition of mammosphere formation, xenograft growth, and metastasis in EGFR-positive breast cancer cells that overexpressed xCT \[[@B162-cancers-11-01021]\].

### 3.2.2. Cell-Based Therapy {#sec3dot2dot2-cancers-11-01021}

Different and conflicting data from the literature indicate that MSCs can promote tumor growth and progression through their ability to home in on the tumor microenvironment \[[@B163-cancers-11-01021]\]. It is thanks to this capacity that preclinical studies have suggested MSCs as anti-cancer drug delivery carriers \[[@B164-cancers-11-01021],[@B165-cancers-11-01021],[@B166-cancers-11-01021]\]. In particular, it has been reported that MSCs can uptake and subsequently slowly release paclitaxel through exosomes, inhibiting the proliferation of different cancer cells \[[@B164-cancers-11-01021],[@B165-cancers-11-01021],[@B166-cancers-11-01021],[@B167-cancers-11-01021],[@B168-cancers-11-01021],[@B169-cancers-11-01021]\]. As reported by Scioli et al., adipose-derived stem cells (ASCs) can uptake and release paclitaxel inhibiting CG5 breast cancer survival and proliferation, with no effects on ASC viability and cell cycle \[[@B170-cancers-11-01021]\]. Moreover, it has been demonstrated that gold nanorod embedded hollow periodic mesoporous organosilica nanospheres (GNR\@HPMOs) possess high paclitaxel-loading capability, excellent photothermal transfer ability upon near-infrared (NIR) light irradiation, and are well-retained by MSCs after internalization without affecting their viability and tumor-homing capability \[[@B171-cancers-11-01021]\]. Some experiments revealed that GNR\@HPMOs-paclitaxel loaded MSCs showed synergistic chemo-photothermal killing effects on breast cancer cells in vitro and in vivo \[[@B171-cancers-11-01021]\]. Genetically engineered ASCs overexpressing TNFα were able to induce apoptosis, via caspase 3/7 activation, in human breast cancer cells and melanoma xenografts \[[@B172-cancers-11-01021]\]. However, there are several limitations, principally regarding safety, that currently prevent the application of MSC-based strategies in clinical trials.

### 3.2.3. Gene-Targeted Therapies {#sec3dot2dot3-cancers-11-01021}

Currently, therapeutic small interfering RNAs (siRNAs) and microRNAs (miRNAs) represent potential tools for specific gene targeting. Many preclinical studies have been carried out to explore their efficacy in cancer therapy \[[@B173-cancers-11-01021]\]. Commonly, nanoparticles are used as carriers in order to prevent RNA degradation and ensure the delivery to the tumor site \[[@B174-cancers-11-01021]\]. Several siRNA-based therapeutics are in use in cancer patients, instead of miRNA applications, which are still in the preclinical stage. In 2008, the first targeted delivery of siRNA was accomplished in humans. A phase I trial using the siRNA CALAA-01 showed an inhibition of tumor growth by targeting ribonucleotide reductase in patients with advanced solid tumors ([Table 2](#cancers-11-01021-t002){ref-type="table"}). The nanoparticles, which contained the siRNA, was made of a cyclodextrin-based polymer, a human transferrin protein (TF)-targeting ligand to engage TF receptors on the surface of the cancer cells and a hydrophilic polymer (polyethylene glycol, PEG) used to promote nanoparticle stability in biological fluids. Instrumental analysis confirmed the presence of nanoparticles in the tumor site with low toxicity \[[@B109-cancers-11-01021],[@B110-cancers-11-01021]\].

Atu027 is a siRNA directed against serine/threonine-protein kinase N3 (PKN3), an angiogenic regulator expressed in the vascular endothelium \[[@B111-cancers-11-01021]\]. The siRNA, formulated as liposomal particles (AtuPLEX18), is currently used in an ongoing phase I study in patients with advanced refractory solid tumors, including breast cancer, and has been proven effective as an anti-tumor agent \[[@B111-cancers-11-01021]\].

Only one phase I/II clinical trial has been performed using a liposomal miR-34a mimic, MRX34, which showed antitumor activity in patients with advanced solid tumors, including breast cancer \[[@B112-cancers-11-01021]\]. miR-34 is a tumor suppressor and it has been found to be lost or repressed in cancer patients \[[@B175-cancers-11-01021]\]. It has been reported that miRNAs are involved in the post-transcriptional regulation of breast-cancer-related genes \[[@B176-cancers-11-01021]\]. Antagomirs are small synthetic oligonucleotides involved in the silencing of endogenous miRNAs. The treatment with the anti-miR21 antagomir of MDA-MB-231 cells resulted in the reversion of the EMT and CSC phenotypes \[[@B177-cancers-11-01021]\]. In addition, anti-miR10b antagomirs prevented metastasis formation in a mouse mammary tumor model \[[@B178-cancers-11-01021]\].

Small hairpin RNA lentivirus (shRNA) particles for CD44 knockdown in BCSCs have been proven to induce differentiation into non-CSCs with a lower aggressiveness \[[@B179-cancers-11-01021]\]. It has been reported that autophagy, the lysosomal degradation of cellular components, is involved in the survival and maintenance of BCSCs \[[@B180-cancers-11-01021]\]. The knockdown of autophagy specific genes increased the expression of CD24 and the epithelial-like CD44^+^/CD24^+^ phenotype \[[@B180-cancers-11-01021]\]. However, a study by Kumar et al. reported that the induction of early stage autophagy triggered apoptosis in CD44^+^/CD24^−^ BCSCs and the inhibition of autophagosome formation prevented this phenomenon \[[@B181-cancers-11-01021]\].

The use of shRNA for ganglioside GD3 synthase reduced the CSC population and CSC-associated markers in breast cancer cell lines and completely hindered tumor formation in vivo \[[@B182-cancers-11-01021]\]. OncoGenex Technologies Inc. and Isis Pharmaceuticals Inc. developed OGX-011, a clusterin-inhibiting antisense oligonucleotide, a potential sensitizer of solid tumors that are resistant to conventional cancer therapeutics. A phase II clinical trial of OGX-011 in combination with chemotherapeutic drugs is underway for breast cancer patients \[[@B113-cancers-11-01021]\].

3.3. Other Therapeutic Approaches {#sec3dot3-cancers-11-01021}
---------------------------------

Salinomycin, an ionophore antibiotic, has been proven effective in eliminating BCSCs in different breast cancer histotypes, likely by autophagy \[[@B183-cancers-11-01021]\], increasing metastasis-free survival and overall survival, as well as inhibiting mammosphere formation and EMT in vitro \[[@B147-cancers-11-01021],[@B184-cancers-11-01021]\]. Combined treatments with salinomycin, conventional drugs (i.e., doxorubicin or paclitaxel), anti-HER2 targeted therapies (monoclonal antibody trastuzumab and lapatinib), and histone deacetylase inhibitors synergistically counteracted tumor growth \[[@B185-cancers-11-01021],[@B186-cancers-11-01021]\]. In particular, the histone deacetylase inhibitor abexinostat has been proven to promote CSC differentiation in breast cancer cell lines with low X-inactive specific transcript expression \[[@B187-cancers-11-01021]\].

Other strategies involve the ALDH activity in combination with conventional therapies to improve breast cancer patients' outcomes. Croker et al. reported that the inhibition of ALDH activity, by all-trans retinoic acid (ATRA) or diethylaminobenzaldehyde (the specific ALDH inhibitor), counteracted the resistance to chemotherapy (doxorubicin/paclitaxel) and radiotherapy in TNBC cells \[[@B188-cancers-11-01021]\]. In particular, the treatment with ATRA, an inducer of cell differentiation, has been proven to be effective in inhibiting BCSCs \[[@B189-cancers-11-01021]\], but currently, its clinical application (in combination with paclitaxel) has not been successful \[[@B190-cancers-11-01021]\] as an inhibitor. The inhibition of the DNA repair enzyme poly adenosine diphosphate ADP ribose polymerase by Olaparib has proven effective in counteracting CSC activity in breast cancer cells by ERK signaling \[[@B191-cancers-11-01021]\]. It has been reported that the combination with the common chemotherapeutic drug irinotecan induced a decrease in the number of CSCs \[[@B191-cancers-11-01021]\]. Consequently, Olaparib has been proposed as a candidate for the treatment of non-BRCA-related breast cancer \[[@B191-cancers-11-01021]\]. The expression of ATP-binding cassette (ABC) transporters is higher in stem cells compared with normal cells, suggesting a potential role in drug resistance \[[@B192-cancers-11-01021],[@B193-cancers-11-01021]\]. The combined use of dofequidar, an ABC transporter inhibitor, with other chemotherapeutic agents, such as cyclophosphamide, doxorubicin and fluorouracil, demonstrated promising results in patients with advanced or recurrent breast cancer \[[@B194-cancers-11-01021]\]. Dofequidar increased the sensitivity of CSC-like side population cells from different cancer cell lines to anticancer drugs \[[@B195-cancers-11-01021]\]. As described above, conventional chemotherapeutic drugs are not able to target CSCs because of their quiescent state. Therefore, a possible therapeutic strategy is to force CSCs to re-enter the cell cycle, as reported by Gasca et al. \[[@B196-cancers-11-01021]\]. In particular, fbxw7 (F-box protein), a subunit of the stem cell factor SCF-type ubiquitin ligase complex, seems to maintain cell quiescence by reducing the expression of the c-Myc transcriptional factor responsible for the control of the cell cycle and proliferation \[[@B197-cancers-11-01021]\]. Gasc et al. silenced fbxw7 in paclitaxel-resistant TNBC (MDA-MB-468), resensitizing cells to the chemotherapeutic drug item \[[@B196-cancers-11-01021]\]. Moreover, radioresistant BCSCs expressed high levels of ataxia telangiectasia mutated (ATM) (DNA damage surveillance/repair system), and the treatment with an ATM inhibitor has been proven efficacious in re-sensitizing BCSCs to radiation \[[@B198-cancers-11-01021]\].

Finally, different dietary polyphenols seem to affect CSC self-renewal and survival pathways. Among them, sulforaphane from cruciferous vegetables \[[@B199-cancers-11-01021],[@B200-cancers-11-01021]\], epigallocatechin-3-gallate in green tea \[[@B201-cancers-11-01021],[@B202-cancers-11-01021]\], resveratrol \[[@B203-cancers-11-01021],[@B204-cancers-11-01021]\], curcumin \[[@B205-cancers-11-01021]\], and piperine \[[@B205-cancers-11-01021]\] have been reported effective in counteracting BCSC functions.

4. Conclusions {#sec4-cancers-11-01021}
==============

Important evidence supports the pivotal role of tumor-initiating or cancer stem cells in anticancer drug resistance and recurrence. Many efforts have been made in the isolation and characterization of breast cancer stem cells (BCSCs), as well as in the identification of possible markers to specifically target this cell population. Several targets have been proposed for the development of BCSC-directed therapies; however, a combination approach directed toward multiple and different pharmacological targets is the most promising. Unfortunately, the outcome of the applied therapeutic methodologies is inconsistent because of the difficulty, by the current markers, to identify a single small population of cells with a high plasticity. The heterogeneity of the BCSC population sustains the therapeutic strategy based on the combination of multiple targets. In addition, the research of new circulating markers for monitoring the effect of anti-BCSC agents is constantly at work. Nano- and biotechnologies associated with gene-targeted strategies represent a promising approach in the development of efficacious drugs targeting CSCs and are able to improve breast cancer therapies.
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![An overview of the main strategies based on BCSC-targeting. After systemic application, engineered immune cells or mesenchymal stem cells (MSCs), tailored to the molecular profile of patients' breast cancer, home in on the tumor microenvironment and release different specific anti-CSC drugs (proteins, enzymes, recombinant DNA, miRNAs, siRNAs, and chemotherapeutics). Nanoparticles containing different anti-CSC molecules can be administered alone or incorporated into MSCs to reach the tumor microenvironment and deliver drugs.](cancers-11-01021-g001){#cancers-11-01021-f001}
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###### 

CTC-targeting strategies for breast cancer prognosis.

  ------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------- ------------------------------ ------------------------------------ --------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -----------------------------
  **Epithelial(E)-CTC measurement through Ep-CAM-based systems**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
  **Study Design**                                                                                                                            **Study Population**                            **Patients**                   **Patients Positive for CTCs (%)**   **CTC Cut-Off**                                           **Overall Survival**                                                                                                                                     **Progression-Free Survival**                                                                                                       **Disease-Free Survival**                                **Notes**                                                                                                                                                                                                                                       **Ref.**
  Prospective multicentric study                                                                                                              Metastatic breast cancer                        177                            87 (49%)                             ≥5 CTCs/ 7.5 mL of PB                                     \>18 months CTC-negative group vs. 10.1 months CTC positive group *p* \< 0.001                                                                           7.0 months CTC negative vs. 2.7 months CTC positive, *p* \< 0.001                                                                   N.R.                                                     First validation study which established the positive-threshold value for the CTC count                                                                                                                                                         \[[@B30-cancers-11-01021]\]
  Retrospective multicentric study                                                                                                            Metastatic breast cancer                        1944 (911 positive for CTCs)   911 (46.9%)                          ≥5 CTCs/ 7.5 mL of PB                                     HR 2.78 for CTC-positive group (95% CI 2.42--3.19, *p* \< 0.001)                                                                                         HR 1.92 for CTC-positive group (95% CI 1.73--2.14, *p* \< 0.0001)                                                                   N.R.                                                     A positive CTC-count had a significant prognostic value also at 3-5 weeks after the baseline count and at 6-8 week after the first treatment dose. CTC count improved the predictive value of the full clinicopathological prognostic model     \[[@B31-cancers-11-01021]\]
  Retrospective multicentric study                                                                                                            Non-metastatic breast cancer (Stage I to III)   3173                           640 (20.2%)                          ≥1 CTC/ 7.5 mL of PB                                      HR 1.97 for CTC-positive group (95% CI, 1.51 to 2.59 *p* \< 0.001)                                                                                       N.R.                                                                                                                                HR, 1.82 for CTC-positive group (95% CI), 1.47 to 2.26   In non-metastatic breast cancer patients, CTC count was confirmed as an independent prognostic factor                                                                                                                                           \[[@B32-cancers-11-01021]\]
  Meta-analysis                                                                                                                               Stage I to IV breast cancer                     550                            N.A.                                 ≥1 HER2/neu positive CTC/ 7.5 mL of PB                    In patients without metastasis, Her2-positive CTCs associated with HR 2.273 (95% CI: 1.340--3.853, *p* = 0.002)                                          In patients without metastasis, HER2/neu-positive CTCs associated with HR = 2.870 (95% CI: 1.298--6.343, *p* = 0.009)               N.R.                                                     HER2/neu-positive CTCs were associated with worse OS and PFS in non-metastatic patients only (non-significant in metastatic patients). This was independent from the HER2/neu status of the primitive tumor                                     \[[@B42-cancers-11-01021]\]
  **Non-Ep-CAM-based systems (measuring both epithelial (E)-CTCs, biphenotypic epithelial/mesenchymal (EM)-CTCs, and mesenchymal (M)-CTCs**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
  **Study Design**                                                                                                                            **Study Population**                            **Patients**                   **Patients Positive for CTCs (%)**   **CTC Cut-Off**                                           **Overall Survival**                                                                                                                                     **Progression-Free Survival**                                                                                                       **Disease-Free Survival**                                **Notes**                                                                                                                                                                                                                                       **Ref.**
  Prospective observational study                                                                                                             Metastatic breast cancer                        56                             47 (83%)                             N.A.                                                      HR 1.035 for EM-CTC positive patients (95% CI, 1.013 to 1.057 *p* = 0.0016) HR 1.019 for E-CTC positive patients (95% CI, 1.004 to 1.034 *p* = 0.0013)   HR 1.021 for EM-CTC positive patients (95% CI 1.004--1.039 *p* = 0.016)                                                             N.R.                                                     Different sub-populations of CTCs were evaluated. Expression of both epithelial and mesenchymal markers was associated to a reduced OS and PFS. CTCs negative for both epithelial and mesenchymal markers were associated with CNS metastases   \[[@B53-cancers-11-01021]\]
  Prospective, randomized, open-labeled phase III study                                                                                       HER2-negative metastatic breast cancer          108                            90 (83.3%)                           CTCs ≥ 10/ 5 mL PB with a proportion of M-CTCs \> 10.7%   N.R.                                                                                                                                                     6.2 months for patients with ≥ 10 CTCs and with a proportion of M-CTCs \> 10.7% vs. 9.9 months for the other groups (*p* = 0.010)   Non-significant                                          Validation study for the CanPatrol CTC enrichment technique. All the three sub-populations of CTCs were evaluated. The follow-up was of 12 months                                                                                               \[[@B54-cancers-11-01021]\]
  ------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------- ------------------------------ ------------------------------------ --------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -----------------------------

Abbreviations: Ref.---References; CTC(s)---circulating tumor cell(s); PB---peripheral blood; HR---hazard ratio; N.R.---Not Reported; N.A.---Not Applicable.
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###### 

List of BCSC-targeted strategies used in clinical trials.

  Strategy                                                                                Target                                                                                            Drug                                                                                        Phase                          Status                        Stage/Type                     Identifier                     Reference
  --------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------- ------------------------------ ----------------------------- ------------------------------ ------------------------------ -------------------------------------------------------
  **Notch signaling**                                                                     γ-Secretase                                                                                       MK-0752                                                                                     Pilot-study                    Unknown                       Early stage BC                 NCT00756717                    \[[@B82-cancers-11-01021]\]
  I/II                                                                                    Completed                                                                                         Advanced or metastatic                                                                      NCT00645333                    \[[@B24-cancers-11-01021]\]                                                                 
  I                                                                                       Completed                                                                                         Metastatic or advanced                                                                      NCT00106145                    \[[@B73-cancers-11-01021]\]                                                                 
  PF-03084014 (Nirogacestat)                                                              I                                                                                                 Completed                                                                                   Advanced                       NCT01876251                   \[[@B83-cancers-11-01021]\]                                   
  II                                                                                      Completed                                                                                         Advanced                                                                                    NCT02299635                    \[[@B84-cancers-11-01021]\]                                                                 
  LY3039478 (Crenigacestat)                                                               I                                                                                                 Recruiting                                                                                  Advanced or metastatic         NCT02784795                   \[[@B85-cancers-11-01021]\]                                   
  RO4929097 (RG-4733)                                                                     I                                                                                                 Completed                                                                                   Advanced                       NCT01208441                   \[[@B82-cancers-11-01021]\]                                   
  I                                                                                       Completed                                                                                         Advanced                                                                                    NCT01238133                    \[[@B86-cancers-11-01021]\]                                                                 
  I                                                                                       Completed                                                                                         Metastatic                                                                                  NCT01071564                    \[[@B76-cancers-11-01021]\]                                                                 
  I                                                                                       Completed                                                                                         Advanced or metastatic                                                                      NCT01149356                    \[[@B86-cancers-11-01021]\]                                                                 
  II                                                                                      Completed                                                                                         Advanced, metastatic or recurrent                                                           NCT01151449                    \[[@B82-cancers-11-01021]\]                                                                 
  I                                                                                       Completed                                                                                         Refractory                                                                                  NCT01158274                    \[[@B82-cancers-11-01021]\]                                                                 
  I                                                                                       Completed                                                                                         Advanced                                                                                    NCT01131234                    \[[@B87-cancers-11-01021]\]                                                                 
  Protein-protein interaction                                                             CB-103                                                                                            I/II                                                                                        Recruiting                     Advanced or metastatic        NCT03422679                    \[[@B88-cancers-11-01021]\]    
  **Hedgehog signaling**                                                                  Hedgehog/PTCH1                                                                                    GDC-0449 (vismodegib)                                                                       II                             Recruiting                    TNBC                           NCT02694224                    \[[@B88-cancers-11-01021]\]
  LDE225 (sonidegib)                                                                      I                                                                                                 Unknown                                                                                     Advanced                       NCT02027376                   \[[@B88-cancers-11-01021]\]                                   
  I                                                                                       Completed                                                                                         Metastatic                                                                                  NCT01576666                    \[[@B89-cancers-11-01021]\]                                                                 
  **HDAC signaling**                                                                      HDAC                                                                                              Vorinostat                                                                                  I/II                           Terminated                    Advanced                       NCT01118975                    \[[@B90-cancers-11-01021]\]
  **HER2 signaling**                                                                      HER2                                                                                              Lapatinib Ditosylate                                                                        II                             Recruiting                    Advanced or metastatic         NCT01868503                    \-
  Lapatinib                                                                               II                                                                                                Ongoing, not recruiting                                                                     Advanced or metastatic         NCT00524303                   \[[@B25-cancers-11-01021]\]                                   
  **TGF-βIR signaling**                                                                   Clusterin                                                                                         Anti-clusterin mAb AB-16B5                                                                  I                              Completed                     Advanced                       NCT02412462                    \[[@B91-cancers-11-01021]\]
  TGF-βIR                                                                                 Galunisertib/LY2157299                                                                            II                                                                                          Completed                      Metastatic                    NCT02538471                    \[[@B92-cancers-11-01021]\]    
  **PI3K/Akt signaling**                                                                  mTOR                                                                                              Everolimus (RAD001)                                                                         III                            Completed                     Advanced                       NCT00863655                    \[[@B93-cancers-11-01021]\]
  Akt                                                                                     MK2206                                                                                            I                                                                                           Ongoing, not recruiting        Advanced                      NCT01281163                    \[[@B94-cancers-11-01021]\]    
  **Ephrin signaling**                                                                    EFNA4                                                                                             PF-06647263                                                                                 I                              Completed                     Advanced                       NCT02078752                    \[[@B95-cancers-11-01021]\]
  **VEGF signaling**                                                                      HSP90                                                                                             Ganetespib                                                                                  I                              Completed                     Metastatic HER2^+^             NCT02060253                    \[[@B96-cancers-11-01021]\]
  **CXCR signaling**                                                                      CXCR                                                                                              Reparixin                                                                                   II                             Recruiting                    Metastatic                     NCT01861054                    \[[@B97-cancers-11-01021]\]
  CXCR                                                                                    Reparixin                                                                                         I                                                                                           Ongoing, not recruiting        Metastatic                    NCT02001974                    \[[@B73-cancers-11-01021]\]    
  **Wnt signaling**                                                                       PORCN                                                                                             LGK-974 (WNT974)                                                                            I                              Recruiting                    TNBC                           NCT01351103                    \[[@B98-cancers-11-01021]\]
  Wnt-5a mimic                                                                            Foxy-5                                                                                            I                                                                                           Completed                      Metastatic                    NCT02020291                    \[[@B99-cancers-11-01021]\]    
  Recruiting                                                                              Metastatic                                                                                        NCT02655952                                                                                 \[[@B100-cancers-11-01021]\]                                                                                               
  FZD receptors                                                                           OMP-18R5 (ventictumab)                                                                            I                                                                                           Completed                      Metastatic                    NCT01973309                    \[[@B101-cancers-11-01021]\]   
  ROR1                                                                                    UC-961 (Cirmtuzumab)                                                                              I                                                                                           Not recruiting                 Metastatic                    NCT02776917                    \-                             
  **Immunomodulation**                                                                    CSC                                                                                               CSC whole                                                                                   I/II                           Completed                     Advanced                       NCT02063893                    \[[@B26-cancers-11-01021]\]
  Mammoglobin-A                                                                           Vaccination with a pasmid DNA encoding mammaglobin-A                                              I                                                                                           Completed                      Metastatic                    NCT00807781                    \[[@B102-cancers-11-01021]\]   
  Vaccination with a plasmid DNA encoding mammaglobin-A                                   I                                                                                                 Recruiting                                                                                  Advanced                       NCT02204098                   \[[@B103-cancers-11-01021]\]                                  
  CYP1B1                                                                                  Vaccination with a plasmid DNA encoding CYP1B1 encapsulated in biodegradable microparticles       I                                                                                           Completed                      Advanced                      NCT00381173                    \-                             
  Multiple antigens                                                                       Plasmid-based vaccination strategy targeting multiple antigens of cancer stem cells               I                                                                                           Recruiting                     Advanced                      NCT02157051                    \-                             
  IGFBP2, HER2 and IGF1R                                                                  Vaccination with a plasmid encoding IGFBP2, HER2 and IGF1R                                        I                                                                                           Recruiting                     Advanced                      NCT02780401                    \-                             
  HER2                                                                                    Vaccination with a plasmid DNA encoding HER2                                                      I                                                                                           Ongoing                        Advanced                      NCT00436254                    \-                             
  Polypitopes DNA                                                                         Personalized polyepitope DNA vaccine                                                              I                                                                                           Recruiting                     Advanced                      NCT02348320                    \-                             
  RNA vaccines                                                                            Immunogenic RNA vaccines                                                                          I                                                                                           Recruiting                     Advanced                      NCT02316457                    \-                             
  HER peptide (NeuVax)                                                                    Vaccination with a HER2-targeted peptide (NeuVax)                                                 III                                                                                         Ongoing                        Advanced                      NCT01479244                                                   
  Peptide (GP2 and AE37)                                                                  Vaccination with a HER2-targeted peptide (GP2 and AE37)                                           II                                                                                          Ongoing                        Advanced                      NCT00524277                    \[[@B104-cancers-11-01021]\]   
  Synthetic long peptide                                                                  Vaccination with personalized synthetic long peptide vaccine                                      I                                                                                           Recruiting                     Advanced                      NCT02427581                    \-                             
  Alpha peptide                                                                           Vaccination with folate receptor alpha peptide vaccine                                            I                                                                                           Recruiting                     Advanced                      NCT02593227                    \-                             
  Peptides tumor-associated                                                               Vaccination with four tumor-associated peptides                                                   I                                                                                           Recruiting                     Rdvanced                      NCT02826434                    \-                             
  GM-CSF                                                                                  Vaccination with autologous or allogeneic breast cancer cells engineered to secrete GM-CSF        I                                                                                           Ongoing                        Metastatic                    NCT00399529 NCT00317603        \-                             
  TP53                                                                                    Anti-TP53 TCR-gene engineered lymphocytes and autologous dendritic cell-adenovirus TP53 vaccine   I                                                                                           Completed                      Metastatic                    NCT00704938                    \-                             
  Recombinant fusion protein of IL-2 linked to a single-chain TCR domain targeting TP53   I                                                                                                 Completed                                                                                   Metastatic                     NCT00496860                   \-                                                            
  Tumor antigen                                                                           Immunotherapy with modified TCR targeting CEA tumor antigen                                       I                                                                                           Ongoing, recruiting            Metastatic                    NCT01022138 NCT02349724        \[[@B105-cancers-11-01021]\]   
  Mesothelin                                                                              CAR-T cells targeting mesothelin                                                                  I                                                                                           Recruiting                     Advanced                      NCT0258074 NCT02792114         \-                             
  CD133                                                                                   CAR-T cells targeting CD133                                                                       I                                                                                           Recruiting                     Advanced                      NCT02541370                    \-                             
  EpCAM                                                                                   CAR-T cells targeting EpCAM                                                                       I                                                                                           Recruiting                     Recurrent                     NCT02915445                    \-                             
  ROR1                                                                                    CAR-T cells targeting ROR1                                                                        I                                                                                           Recruiting                     Recurrent                     NCT02706392                    \[[@B106-cancers-11-01021]\]   
  MUC-1                                                                                   CAR-T cells targeting MUC-1                                                                       I/II                                                                                        Recruiting                     Advanced                      NCT02587689                    \-                             
  HER2                                                                                    CAR-T cells targeting HER2                                                                        I/II                                                                                        Recruiting                     Recurrent                     NCT02547961 NCT02713984        \-                             
  MET                                                                                     CAR-T cells targeting MET proto-oncogene                                                          I/II                                                                                        Ongoing                        Advanced                      NCT01837602                    \[[@B107-cancers-11-01021]\]   
  TP53                                                                                    Vaccination with adenovirus-TP53 trasduced DCs                                                    I/II                                                                                        Ongoing                        Recurrent and advanced        NCT01042535                    \[[@B108-cancers-11-01021]\]   
  HER2                                                                                    Vaccination with adenovirus-HER2- trasduced DCs                                                   I                                                                                           Completed                      Advanced                      NCT00197522 NCT01730118        \-                             
  Cyclin B1/WT-1/CEF                                                                      Vaccination cyclin B1/WT-1/CEF pool-loaded DCs                                                    I                                                                                           Recruiting                     Advanced                      NCT02018458                    \-                             
  Onco-peptides                                                                           Vaccination with autologous DCs pulsed with onco-peptides                                         I                                                                                           Completed                      Metastatic                    NCT00197925                    \-                             
  Tumor blood vessel antigen -derived peptides                                            Vaccination with DCs incorporating tumor blood vessel antigen-derived peptides                    I                                                                                           Recruiting                     Metastatic                    NCT02479230                    \-                             
  Frizzled (Fzd) receptor                                                                 Vantictumab/OMP-18R5 Anti-Frizzled receptors mAb                                                  Ib                                                                                          Completed                      Metastatic                    NCT01973309                    \-                             
  **Gene-targeting**                                                                      RRM2                                                                                              CALAA-01 (transferin-targeted cyclodextrin-containing polymer carrying siRNA against RRM2   I                              Completed                     Advanced                       NCT00689065                    \[[@B109-cancers-11-01021],[@B110-cancers-11-01021]\]
  Protein kinase N3 gene                                                                  Lipoplexed Atu-027 (AtuPLEX)                                                                      I                                                                                           Recruiting                     Advanced                      NCT00938574                    \[[@B111-cancers-11-01021]\]   
  MiR-34a                                                                                 MRX34 liposomal miR-34a mimic                                                                     I                                                                                           Completed                      Advanced                      NCT01829971                    \[[@B112-cancers-11-01021]\]   
  Clusterin                                                                               OGX01 antisense oligonucleotide                                                                   II                                                                                          Completed                      Metastatic                    NCT01578655                    \[[@B113-cancers-11-01021]\]   

[^1]: These authors contributed equally to this work.
